IL2 and cancer: When using TETP as cancer cell-selective promoter to restrict IL-2 and CD40L transgene expression to melanoma cells, tight expression was demonstrated, which was only 5 to 40-fold lower than those from vectors controlled by the nonselective CMV promoter.